Guillain Barré Syndrome and its variants as a manifestation of COVID-19 : A systematic review of case reports and case series
Copyright © 2020 Elsevier B.V. All rights reserved..
BACKGROUND: The COVID-19 pandemic caused by SARS-COV-2 began in Wuhan, China in December 2019. Reports of COVID-19 with central (CNS) and peripheral nervous (PNS) system manifestations are emerging. In this systematic review, we compared and summarized the demographics, clinical features, Brighton criteria, immunological and laboratory findings with a focus on modified Erasmus GBS Outcome Score (mEGOS) in SARS-CoV-2 patients with GBS and its variants.
METHODS: Based on PRISMA guidelines, we searched three databases (PubMed, Scopus, and Google Scholar) for studies on COVID-19 and GBS between December 1, 2019 to July 15, 2020. For descriptive analysis, we studied two groups with: 1) acute inflammatory demyelinating polyradiculoneuropathy (AIDP) variant, and 2) Non-AIDP/Other variants. We compared mEGOS scores for patients in both groups along with other key clinical features.
RESULTS: Of the 50 GBS cases identified from 37 studies, 33 (66%) had acute inflammatory demyelinating polyradiculopolyneuropathy (AIDP) while 17 (34%) were of other (non-AIDP) variants. There mEGOS scores did not differ between AIDP patients and AMAN/AMSAN patients. Majority of the AIDP (66.7%) and AMAN/AMSAN (57.2%) patients belonged to Brighton level 1 indicating maximum diagnostic certainty.
CONCLUSION: To our knowledge, this is among the first reviews that includes GBS variants and the clinical prediction tool mEGOS for prognostication in COVID-19 patients. Further research is needed to assess whether IVIG is preferable over plasmapheresis in this population of GBS patients. It would also be crucial to follow these patients over time to identify the long-term disability as well as treatment outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:420 |
|---|---|
| Enthalten in: |
Journal of the neurological sciences - 420(2021) vom: 15. Jan., Seite 117263 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sriwastava, Shitiz [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AIDP |
|---|
| Anmerkungen: |
Date Completed 09.02.2021 Date Revised 30.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jns.2020.117263 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318864673 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318864673 | ||
| 003 | DE-627 | ||
| 005 | 20240330234556.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jns.2020.117263 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1356.xml |
| 035 | |a (DE-627)NLM318864673 | ||
| 035 | |a (NLM)33321326 | ||
| 035 | |a (PII)S0022-510X(20)30599-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sriwastava, Shitiz |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Guillain Barré Syndrome and its variants as a manifestation of COVID-19 |b A systematic review of case reports and case series |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.02.2021 | ||
| 500 | |a Date Revised 30.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: The COVID-19 pandemic caused by SARS-COV-2 began in Wuhan, China in December 2019. Reports of COVID-19 with central (CNS) and peripheral nervous (PNS) system manifestations are emerging. In this systematic review, we compared and summarized the demographics, clinical features, Brighton criteria, immunological and laboratory findings with a focus on modified Erasmus GBS Outcome Score (mEGOS) in SARS-CoV-2 patients with GBS and its variants | ||
| 520 | |a METHODS: Based on PRISMA guidelines, we searched three databases (PubMed, Scopus, and Google Scholar) for studies on COVID-19 and GBS between December 1, 2019 to July 15, 2020. For descriptive analysis, we studied two groups with: 1) acute inflammatory demyelinating polyradiculoneuropathy (AIDP) variant, and 2) Non-AIDP/Other variants. We compared mEGOS scores for patients in both groups along with other key clinical features | ||
| 520 | |a RESULTS: Of the 50 GBS cases identified from 37 studies, 33 (66%) had acute inflammatory demyelinating polyradiculopolyneuropathy (AIDP) while 17 (34%) were of other (non-AIDP) variants. There mEGOS scores did not differ between AIDP patients and AMAN/AMSAN patients. Majority of the AIDP (66.7%) and AMAN/AMSAN (57.2%) patients belonged to Brighton level 1 indicating maximum diagnostic certainty | ||
| 520 | |a CONCLUSION: To our knowledge, this is among the first reviews that includes GBS variants and the clinical prediction tool mEGOS for prognostication in COVID-19 patients. Further research is needed to assess whether IVIG is preferable over plasmapheresis in this population of GBS patients. It would also be crucial to follow these patients over time to identify the long-term disability as well as treatment outcomes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a AIDP | |
| 650 | 4 | |a AMSAN | |
| 650 | 4 | |a Bickerstaff encephalitis | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a GBS | |
| 650 | 4 | |a MFS | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Kataria, Saurabh |e verfasserin |4 aut | |
| 700 | 1 | |a Tandon, Medha |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Jenil |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Riddhi |e verfasserin |4 aut | |
| 700 | 1 | |a Jowkar, Abbas |e verfasserin |4 aut | |
| 700 | 1 | |a Daimee, Maha |e verfasserin |4 aut | |
| 700 | 1 | |a Bernitsas, Evanthia |e verfasserin |4 aut | |
| 700 | 1 | |a Jaiswal, Preeti |e verfasserin |4 aut | |
| 700 | 1 | |a Lisak, Robert P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the neurological sciences |d 1964 |g 420(2021) vom: 15. Jan., Seite 117263 |w (DE-627)NLM000061956 |x 1878-5883 |7 nnns |
| 773 | 1 | 8 | |g volume:420 |g year:2021 |g day:15 |g month:01 |g pages:117263 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jns.2020.117263 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 420 |j 2021 |b 15 |c 01 |h 117263 | ||